NCT00581035View on ClinicalTrials.gov

Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time

PHASE4CompletedINTERVENTIONAL

Enrollment

712

Participants

Timeline

Start Date

January 31, 2006

Study Completion Date

May 31, 2007

Conditions

Healthy

Interventions

BIOLOGICAL

Prevenar and Meningitec

1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months

BIOLOGICAL

Prevenar

1 dose at 2,3.5,6 and 12 months

BIOLOGICAL

Meningitec

1 dose at 2,6 and 12 months

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00581035 - Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time | Biotech Hunter | Biotech Hunter